176 related articles for article (PubMed ID: 25260916)
1. RANTES/CCL5 mediated-biological effects depend on the syndecan-4/PKCα signaling pathway.
Maillard L; Saito N; Hlawaty H; Friand V; Suffee N; Chmilewsky F; Haddad O; Laguillier C; Guyot E; Ueyama T; Oudar O; Sutton A; Charnaux N
Biol Open; 2014 Sep; 3(10):995-1004. PubMed ID: 25260916
[TBL] [Abstract][Full Text] [Related]
2. RANTES/CCL5-induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans.
Suffee N; Hlawaty H; Meddahi-Pelle A; Maillard L; Louedec L; Haddad O; Martin L; Laguillier C; Richard B; Oudar O; Letourneur D; Charnaux N; Sutton A
Angiogenesis; 2012 Dec; 15(4):727-44. PubMed ID: 22752444
[TBL] [Abstract][Full Text] [Related]
3. Syndecan-1 and syndecan-4 are involved in RANTES/CCL5-induced migration and invasion of human hepatoma cells.
Charni F; Friand V; Haddad O; Hlawaty H; Martin L; Vassy R; Oudar O; Gattegno L; Charnaux N; Sutton A
Biochim Biophys Acta; 2009 Oct; 1790(10):1314-26. PubMed ID: 19632304
[TBL] [Abstract][Full Text] [Related]
4. RANTES (CCL5) induces a CCR5-dependent accelerated shedding of syndecan-1 (CD138) and syndecan-4 from HeLa cells and forms complexes with the shed ectodomains of these proteoglycans as well as with those of CD44.
Charnaux N; Brule S; Chaigneau T; Saffar L; Sutton A; Hamon M; Prost C; Lievre N; Vita C; Gattegno L
Glycobiology; 2005 Feb; 15(2):119-30. PubMed ID: 15355933
[TBL] [Abstract][Full Text] [Related]
5. Angiogenic properties of the chemokine RANTES/CCL5.
Suffee N; Richard B; Hlawaty H; Oudar O; Charnaux N; Sutton A
Biochem Soc Trans; 2011 Dec; 39(6):1649-53. PubMed ID: 22103502
[TBL] [Abstract][Full Text] [Related]
6. Binding of the CC-chemokine RANTES to syndecan-1 and syndecan-4 expressed on HeLa cells.
Slimani H; Charnaux N; Mbemba E; Saffar L; Vassy R; Vita C; Gattegno L
Glycobiology; 2003 Sep; 13(9):623-34. PubMed ID: 12773479
[TBL] [Abstract][Full Text] [Related]
7. Pro-angiogenic effect of RANTES-loaded polysaccharide-based microparticles for a mouse ischemia therapy.
Suffee N; Le Visage C; Hlawaty H; Aid-Launais R; Vanneaux V; Larghero J; Haddad O; Oudar O; Charnaux N; Sutton A
Sci Rep; 2017 Oct; 7(1):13294. PubMed ID: 29038476
[TBL] [Abstract][Full Text] [Related]
8. Interaction of RANTES with syndecan-1 and syndecan-4 expressed by human primary macrophages.
Slimani H; Charnaux N; Mbemba E; Saffar L; Vassy R; Vita C; Gattegno L
Biochim Biophys Acta; 2003 Oct; 1617(1-2):80-8. PubMed ID: 14637022
[TBL] [Abstract][Full Text] [Related]
9. RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement.
Roscic-Mrkic B; Fischer M; Leemann C; Manrique A; Gordon CJ; Moore JP; Proudfoot AE; Trkola A
Blood; 2003 Aug; 102(4):1169-77. PubMed ID: 12714503
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidic acid inhibits CC chemokine ligand 5/RANTES production by blocking IRF-1-mediated gene transcription in human bronchial epithelial cells.
Matsuzaki S; Ishizuka T; Hisada T; Aoki H; Komachi M; Ichimonji I; Utsugi M; Ono A; Koga Y; Dobashi K; Kurose H; Tomura H; Mori M; Okajima F
J Immunol; 2010 Oct; 185(8):4863-72. PubMed ID: 20861350
[TBL] [Abstract][Full Text] [Related]
11. Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells.
Sutton A; Friand V; Papy-Garcia D; Dagouassat M; Martin L; Vassy R; Haddad O; Sainte-Catherine O; Kraemer M; Saffar L; Perret GY; Courty J; Gattegno L; Charnaux N
Mol Cancer Ther; 2007 Nov; 6(11):2948-58. PubMed ID: 18025279
[TBL] [Abstract][Full Text] [Related]
12. Syndecan-4 proteoglycan cytoplasmic domain and phosphatidylinositol 4,5-bisphosphate coordinately regulate protein kinase C activity.
Oh ES; Woods A; Lim ST; Theibert AW; Couchman JR
J Biol Chem; 1998 Apr; 273(17):10624-9. PubMed ID: 9553124
[TBL] [Abstract][Full Text] [Related]
13. Regulation of RANTES/CCL5 expression in human astrocytes by interleukin-1 and interferon-beta.
Kim MO; Suh HS; Brosnan CF; Lee SC
J Neurochem; 2004 Jul; 90(2):297-308. PubMed ID: 15228586
[TBL] [Abstract][Full Text] [Related]
14. Differential activation of NF-kappa B, AP-1, and C/EBP in endotoxin-tolerant rats: mechanisms for in vivo regulation of glomerular RANTES/CCL5 expression.
Pocock J; Gómez-Guerrero C; Harendza S; Ayoub M; Hernández-Vargas P; Zahner G; Stahl RA; Thaiss F
J Immunol; 2003 Jun; 170(12):6280-91. PubMed ID: 12794161
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor-specific modulation of cellular response by syndecan-4.
Horowitz A; Tkachenko E; Simons M
J Cell Biol; 2002 May; 157(4):715-25. PubMed ID: 12011116
[TBL] [Abstract][Full Text] [Related]
16. A natural CCL5/RANTES variant antagonist for CCR1 and CCR3.
Capoulade-Métay C; Ayouba A; Kfutwah A; Lole K; Pêtres S; Dudoit Y; Deterre P; Menu E; Barré-Sinoussi F; Debré P; Theodorou I
Immunogenetics; 2006 Jul; 58(7):533-41. PubMed ID: 16791620
[TBL] [Abstract][Full Text] [Related]
17. Elevated plasma RANTES in fibrodysplasia ossificans progressiva - A novel therapeutic target?
Grgurević L; Novak R; Trkulja V; Hamzić LF; Hrkač S; Grazio S; Santini M
Med Hypotheses; 2019 Oct; 131():109313. PubMed ID: 31443758
[TBL] [Abstract][Full Text] [Related]
18. Expression of the chemokines MCP-1/CCL2 and RANTES/CCL5 is differentially regulated by infiltrating inflammatory cells.
Haberstroh U; Pocock J; Gómez-Guerrero C; Helmchen U; Hamann A; Gutierrez-Ramos JC; Stahl RA; Thaiss F
Kidney Int; 2002 Oct; 62(4):1264-76. PubMed ID: 12234296
[TBL] [Abstract][Full Text] [Related]
19. G-protein-coupled receptor agonists differentially regulate basal or tumor necrosis factor-alpha-stimulated activation of interleukin-6 and RANTES in human airway smooth muscle cells.
Huang CD; Ammit AJ; Tliba O; Kuo HP; Penn RB; Panettieri RA; Amrani Y
J Biomed Sci; 2005 Oct; 12(5):763-76. PubMed ID: 16228299
[TBL] [Abstract][Full Text] [Related]
20. The combination of an oxygen-dependent degradation domain-regulated adenovirus expressing the chemokine RANTES/CCL5 and NK-92 cells exerts enhanced antitumor activity in hepatocellular carcinoma.
Li J; Liu H; Li L; Wu H; Wang C; Yan Z; Wang Y; Su C; Jin H; Zhou F; Wu M; Qian Q
Oncol Rep; 2013 Mar; 29(3):895-902. PubMed ID: 23292657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
